The UK Medicines and Healthcare Products Regulatory Agency (MHRA) announced on Friday that it has approved the COVID-19 oral antiviral Paxlovid, Reuters reported.
The new combined treatment is for people with mild to moderate COVID-19, who are at high risk of developing serious disease. They caution that it is still too early to know if the Omicron variant has any impact on the effectiveness of Paxlovid.
The study, Reuters reports, showed that the number of hospitalizations and deaths was 0.8% (3 of 389) in the Paxlovid group compared to 7% (27 of 385) in the placebo group.
The two active principles of Paxlovid They come as separate tablets that are packed together and taken together, twice a day by mouth for 5 days.
The Paxlovid antiviral has been licensed for use in people over 18 years of age who have mild to moderate COVID-19 infection and at least one risk factor for developing serious illness..
Based on data from clinical trials, Paxlovid is most effective when taken during the early stages of infection. They clarify that before Paxlovid is prescribed, the MHRA is advising that current medications for patients should be carefully reviewed.
.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
